Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parathyroid hormone - Takeda

Drug Profile

Parathyroid hormone - Takeda

Alternative Names: 423562; ALX 111; Natpar; Natpara; NPSP-795; NPSP558; Parathyroid hormone (1-84) - Takeda; PREOS; Preotact; PTH (1-84); PTH 1-84; Recombinant human parathyroid hormone-1-84; rhPTH (1-84); rhPTH-1-84; SB-423562; SHP-635; SHP634

Latest Information Update: 18 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NPS Pharmaceuticals
  • Developer National Institutes of Health (USA); NPS Pharmaceuticals; Takeda; Takeda Pharmaceuticals International GmbH
  • Class Calcium regulators; Osteoporosis therapies; Peptide hormones; Recombinant proteins
  • Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants; Parathyroid hormone receptor agonists; Parathyroid hormone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoparathyroidism
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypoparathyroidism; Postmenopausal osteoporosis
  • Phase II Hypocalcaemia
  • Phase I Hypothyroidism
  • Discontinued Osteoporosis

Most Recent Events

  • 15 May 2019 Launched for Hypoparathyroidism (Adjunctive treatment) in Greece, Denmark, Austria, Germany, Norway (SC)
  • 01 May 2019 Phase-I clinical trials in Hypothyroidism in Japan before May 2019 (Takeda pipeline, June 2019)
  • 26 Mar 2019 Final adverse events data from the phase III RACE trial in Hypoparathyroidism presented at the 100th Annual Meeting of the Endocrine Society (ENDO-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top